SIGA Technologies, Inc.

NasdaqGM SIGA

SIGA Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 60.43%

SIGA Technologies, Inc. EBITDA Margin is 60.43% for the Trailing 12 Months (TTM) ending September 30, 2024, a 343.05% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

SIGA Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -24.86%, a -138.44% change year over year.
SIGA Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 64.68%, a 61.84% change year over year.
SIGA Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 39.97%, a -28.41% change year over year.
SIGA Technologies, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 55.82%, a 619.67% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGM: SIGA

SIGA Technologies, Inc.

CEO	Dr. Diem Nguyen M.B.A., Ph.D.
IPO Date	Sept. 10, 1997
Location	United States
Headquarters	31 East 62nd Street
Employees	45
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Key trends

Past 5 years